In Vivo Models of Ovarian Toxicity

Elon C. Roti Roti, Sana M. Salih, Mary Zelinski

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Abstract

    The success of cancer treatment results in female survivors who wrestle with long-term reproductive side effects of chemotherapy. An ideal ovoprotective drug would be mechanism-based, requiring increased knowledge of the action of chemotherapy drugs on the ovary. The strengths and weaknesses of relevant animal models in researching the mechanism of chemotherapy ovarian toxicity and developing ovoprotective therapies are discussed. Emerging in vivo rodent studies reveal that chemotherapeutic agents target multiple ovarian cell types. Most in vivo data assess either acute or long-term ovoprotection from a single chemotherapeutic agent, but direct cross-study efficacy comparisons are difficult due to disparate animal ages and endpoints. Nonetheless, in vivo proof-of-concept studies of some promising ovoprotectants in mice have led to normal offspring. Non-human primate models are necessary to evaluate chemotherapy-induced ovarian toxicity in vivo if the development of ovoprotective agents is to become a clinical reality. Future research on ovarian chemoprotection and design of novel chemotherapeutic agents that are not ovotoxic will transform clinical oncofertility practices for female cancer patients.

    Original languageEnglish (US)
    Title of host publicationCancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity
    PublisherElsevier Inc.
    Pages65-78
    Number of pages14
    ISBN (Print)9780128016015, 9780128015919
    DOIs
    StatePublished - Sep 1 2015

    Fingerprint

    Drug Therapy
    Pharmaceutical Preparations
    Primates
    Survivors
    Ovary
    Rodentia
    Neoplasms
    Animal Models
    Therapeutics

    Keywords

    • Bortezomib
    • Chemotherapy
    • Dexrazoxane
    • Fertility preservation
    • In vivo animal models
    • Mice
    • Non-human primates
    • Ovarian toxicity
    • Ovary
    • Ovoprotectant

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Roti Roti, E. C., Salih, S. M., & Zelinski, M. (2015). In Vivo Models of Ovarian Toxicity. In Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity (pp. 65-78). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801591-9.00005-9

    In Vivo Models of Ovarian Toxicity. / Roti Roti, Elon C.; Salih, Sana M.; Zelinski, Mary.

    Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity. Elsevier Inc., 2015. p. 65-78.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Roti Roti, EC, Salih, SM & Zelinski, M 2015, In Vivo Models of Ovarian Toxicity. in Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity. Elsevier Inc., pp. 65-78. https://doi.org/10.1016/B978-0-12-801591-9.00005-9
    Roti Roti EC, Salih SM, Zelinski M. In Vivo Models of Ovarian Toxicity. In Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity. Elsevier Inc. 2015. p. 65-78 https://doi.org/10.1016/B978-0-12-801591-9.00005-9
    Roti Roti, Elon C. ; Salih, Sana M. ; Zelinski, Mary. / In Vivo Models of Ovarian Toxicity. Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity. Elsevier Inc., 2015. pp. 65-78
    @inbook{1d274214992a43b1bc85cf3f4a6e4d59,
    title = "In Vivo Models of Ovarian Toxicity",
    abstract = "The success of cancer treatment results in female survivors who wrestle with long-term reproductive side effects of chemotherapy. An ideal ovoprotective drug would be mechanism-based, requiring increased knowledge of the action of chemotherapy drugs on the ovary. The strengths and weaknesses of relevant animal models in researching the mechanism of chemotherapy ovarian toxicity and developing ovoprotective therapies are discussed. Emerging in vivo rodent studies reveal that chemotherapeutic agents target multiple ovarian cell types. Most in vivo data assess either acute or long-term ovoprotection from a single chemotherapeutic agent, but direct cross-study efficacy comparisons are difficult due to disparate animal ages and endpoints. Nonetheless, in vivo proof-of-concept studies of some promising ovoprotectants in mice have led to normal offspring. Non-human primate models are necessary to evaluate chemotherapy-induced ovarian toxicity in vivo if the development of ovoprotective agents is to become a clinical reality. Future research on ovarian chemoprotection and design of novel chemotherapeutic agents that are not ovotoxic will transform clinical oncofertility practices for female cancer patients.",
    keywords = "Bortezomib, Chemotherapy, Dexrazoxane, Fertility preservation, In vivo animal models, Mice, Non-human primates, Ovarian toxicity, Ovary, Ovoprotectant",
    author = "{Roti Roti}, {Elon C.} and Salih, {Sana M.} and Mary Zelinski",
    year = "2015",
    month = "9",
    day = "1",
    doi = "10.1016/B978-0-12-801591-9.00005-9",
    language = "English (US)",
    isbn = "9780128016015",
    pages = "65--78",
    booktitle = "Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity",
    publisher = "Elsevier Inc.",

    }

    TY - CHAP

    T1 - In Vivo Models of Ovarian Toxicity

    AU - Roti Roti, Elon C.

    AU - Salih, Sana M.

    AU - Zelinski, Mary

    PY - 2015/9/1

    Y1 - 2015/9/1

    N2 - The success of cancer treatment results in female survivors who wrestle with long-term reproductive side effects of chemotherapy. An ideal ovoprotective drug would be mechanism-based, requiring increased knowledge of the action of chemotherapy drugs on the ovary. The strengths and weaknesses of relevant animal models in researching the mechanism of chemotherapy ovarian toxicity and developing ovoprotective therapies are discussed. Emerging in vivo rodent studies reveal that chemotherapeutic agents target multiple ovarian cell types. Most in vivo data assess either acute or long-term ovoprotection from a single chemotherapeutic agent, but direct cross-study efficacy comparisons are difficult due to disparate animal ages and endpoints. Nonetheless, in vivo proof-of-concept studies of some promising ovoprotectants in mice have led to normal offspring. Non-human primate models are necessary to evaluate chemotherapy-induced ovarian toxicity in vivo if the development of ovoprotective agents is to become a clinical reality. Future research on ovarian chemoprotection and design of novel chemotherapeutic agents that are not ovotoxic will transform clinical oncofertility practices for female cancer patients.

    AB - The success of cancer treatment results in female survivors who wrestle with long-term reproductive side effects of chemotherapy. An ideal ovoprotective drug would be mechanism-based, requiring increased knowledge of the action of chemotherapy drugs on the ovary. The strengths and weaknesses of relevant animal models in researching the mechanism of chemotherapy ovarian toxicity and developing ovoprotective therapies are discussed. Emerging in vivo rodent studies reveal that chemotherapeutic agents target multiple ovarian cell types. Most in vivo data assess either acute or long-term ovoprotection from a single chemotherapeutic agent, but direct cross-study efficacy comparisons are difficult due to disparate animal ages and endpoints. Nonetheless, in vivo proof-of-concept studies of some promising ovoprotectants in mice have led to normal offspring. Non-human primate models are necessary to evaluate chemotherapy-induced ovarian toxicity in vivo if the development of ovoprotective agents is to become a clinical reality. Future research on ovarian chemoprotection and design of novel chemotherapeutic agents that are not ovotoxic will transform clinical oncofertility practices for female cancer patients.

    KW - Bortezomib

    KW - Chemotherapy

    KW - Dexrazoxane

    KW - Fertility preservation

    KW - In vivo animal models

    KW - Mice

    KW - Non-human primates

    KW - Ovarian toxicity

    KW - Ovary

    KW - Ovoprotectant

    UR - http://www.scopus.com/inward/record.url?scp=84967156242&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84967156242&partnerID=8YFLogxK

    U2 - 10.1016/B978-0-12-801591-9.00005-9

    DO - 10.1016/B978-0-12-801591-9.00005-9

    M3 - Chapter

    AN - SCOPUS:84967156242

    SN - 9780128016015

    SN - 9780128015919

    SP - 65

    EP - 78

    BT - Cancer Treatment and the Ovary: Clinical and Laboratory Analysis of Ovarian Toxicity

    PB - Elsevier Inc.

    ER -